• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Bard, Medtronic win Medicare reimbursement add-on for DCBs

August 3, 2015 By Fink Densford

Medtronic, Bard win Medicare add-on coverage for DCBMedtronic (NYSE:MDT) and C.R. Bard (NYSE:BCR) said today that angioplasty treatments with  drug-coated balloons will now be eligible for new technology add-on payments through the Centers for Medicare and Medicaid Services under Medicare’s hospital impatient prospective payment systems.

The add-on payment, with a maximum of $1,036, will help cover additional costs for treating patients for peripheral artery disease with Bard’s Lutonix and Medtronic’s In.Pact Admiral drug-coated balloon during inpatient settings.  The new coverage is slated to go into effect October 1.

“Medtronic has been leading the efforts with CMS to enhance access to DCB technology for the Medicare population, based on the substantially improved clinical outcomes in patients with PAD in the superficial femoral artery treated with theIn.Pact Admiral DCB technology, including significantly fewer repeat interventions and improved quality of life for these patients. Today’s decision will ultimately help to improve patient access to the In.Pact Admiral DCB, which provides significant improvement to the standard of care,” veep of Medtronic’s peripheral vascular business Brian Verrier said in a press release.

Medtronic said the In.Pact DCB won approval for transitional pass-through payment from CMS under the Medicare hospital outpatient prospective payment system in February this year.

“After providing reimbursement in the outpatient setting earlier this year, CMS has now provided additional reimbursement for the Lutonix DCB in the inpatient setting, which demonstrates the benefit to patients from this breakthrough technology,” CEO Timothy Ring said in a prepared statement.

The Lutonix was the first DCB approved by the FDA, C.R. Bard said.

C.R. Bard posted a classic beat-&-raise 2nd quarter last week, topping both sales and earnings expectations and raising its outlook for the rest of the year.

Filed Under: Drug-Device Combinations Tagged With: C.R. Bard, Centers for Medicare and Medicaid Services (CMS)

IN CASE YOU MISSED IT

  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM
  • Lifecare takes next steps in CGM implant development
  • Ypsomed brings autoinjector for dual GCG/GLP-1 delivery to China

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS